Deals channel feed

For­get TIG­IT: No­var­tis’ $1B bet on BeiGene’s ociper­limab ends af­ter com­peti­tors’ set­backs

Last year
R&D

Ex­clu­sive: Pfiz­er to in­vest $25M in­to tiny UK biotech with epi­ge­net­ics ap­proach to can­cer

Last year
Financing

Astel­las eyes rare oph­thal­mol­o­gy, li­cens­ing 4DMT's vi­ral vec­tor for gene ther­a­py for up to $962M

Last year
Cell/Gene Tx

Melin­ta se­cures $142M BAR­DA deal to tar­get pe­di­atric and 'bio­threat' in­di­ca­tions for an­tibi­otics

Last year
Pharma

Ful­crum inks dis­cov­ery deal with Camp4 Ther­a­peu­tics

Last year

BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

Last year
Startups
China

A year af­ter cost cuts, Nanobi­otix has a deal with J&J to li­cense its lead ra­dioen­hancer prod­uct

Last year

Ther­mo Fish­er to ac­quire da­ta in­tel­li­gence com­pa­ny CorE­vi­tas for $900M+

Last year
Pharma
Manufacturing

Pfiz­er in­vests $25M in­to Cari­bou Bio­sciences, gets first dibs on off-the-shelf CAR-T ther­a­py for mul­ti­ple myelo­ma

Last year
Cell/Gene Tx

Te­va re­port­ed­ly con­sid­er­ing sale of API unit

Last year
Manufacturing

Brii Bio­sciences snaps up VBI Vac­ci­nes' HBV pro­grams in ex­pand­ed deal, jump­ing in­to com­mer­cial mode

Last year

Sanofi inks deal to help Sau­di Ara­bia man­u­fac­ture vac­cines lo­cal­ly

Last year
Manufacturing

Pfiz­er, Sam­sung Bi­o­log­ics build on biosim­i­lar deals now worth $897M

Last year
Manufacturing

F-star bags third Take­da tie-up in a year with mul­ti-spe­cif­ic an­ti­bod­ies for can­cer

Last year

De­fense De­part­ment en­lists Evotec to make new an­ti­body treat­ments for Mpox and oth­er pox­es

Last year
R&D

CD­MO Adare Phar­ma So­lu­tions di­vests its post­bi­ot­ic di­vi­sion

Last year
Manufacturing

Swedish man­u­fac­tur­er ac­quires Val­ne­va fa­cil­i­ty

Last year
Manufacturing

No­va­cyt makes cash of­fer for fel­low UK di­ag­nos­tics com­pa­ny as Covid-19 test­ing rev­enue dwin­dles

Last year

All eyes on Brent Saun­ders: Bausch + Lomb deal­mak­er to buy Xi­idra from No­var­tis in $1.75B deal

Last year
Pharma

Au­rinia will ex­plore pos­si­ble sale, fol­low­ing push by share­hold­er

Last year
Pharma

FTC and DOJ pro­pose changes that could slow deal­mak­ing re­view process

Last year
Pharma

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

Last year
Pharma
Cell/Gene Tx

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Last year
R&D

Sh­iono­gi takes an­tibi­ot­ic mak­er un­der its wing in $100M cash buy­out

Last year
First page Previous page 31323334353637 Next page Last page
A service from the Financial Times